Home > Riviste > Minerva Endocrinology > Fascicoli precedenti > Minerva Endocrinologica 2020 September;45(3) > Minerva Endocrinologica 2020 September;45(3):165-71



Opzioni di pubblicazione
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca


Publication history
Per citare questo articolo



Minerva Endocrinologica 2020 September;45(3):165-71

DOI: 10.23736/S0391-1977.20.03137-5


lingua: Inglese

Suboptimal medication adherence may favor the progression of vertebral fractures in women with post-menopausal osteoporosis treated with denosumab

Nazarena BETELLA 1, 2, Emilia BIAMONTE 1, 3, Carmine MATARAZZO 4, Sara PICCINI 1, 3, Roberto OLIVETTI 5, Miriam CELLINI 1, 6, Andrea G. LANIA 1, 3 , Gherardo MAZZIOTTI 1, 3

1 Unit of Endocrinology, Diabetology and Andrology, Section of Bone Diseases and Osteoporosis, IRCCS Humanitas Clinical and Research Center, Rozzano, Milan, Italy; 2 Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy; 3 Department of Biomedical Sciences, Humanitas University, Milan, Italy; 4 Department of Fragility, ASST Carlo Poma, Mantua, Italy; 5 Department of Medicine, ASST Carlo Poma, Mantua, Italy; 6 Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University, Latina, Italy

BACKGROUND: Medication adherence is a determinant of therapeutic outcomes in osteoporotic patients treated with bisphosphonates. In this monocentric study, we evaluated whether the regular drug administration may influence the effectiveness of denosumab in preventing vertebral fractures (VFs) in real-world clinical practice.
METHODS: Two-hundred and four women (median age 75 years, range: 54-90 years) under treatment with denosumab for post-menopausal osteoporosis were longitudinally evaluated for incident radiological VFs and changes in lumbar spine bone mineral density (BMD) in relationship with medication adherence. All patients were persistent with denosumab treatment (i.e., maximum delay in administration of a single denosumab dose: 90 days). Patients were defined adherent to denosumab therapy when the drug was administered every 6 months ±28 days.
RESULTS: One-hundred-seventy-three patients (84.4%) were adherent to denosumab therapy, whereas the remaining 31 patients (15.6%) received in delay one or more denosumab doses (cumulative delay: 52 days, range 29-183 days). Fourteen patients (6.9%) experienced incident VFs during the follow-up (median duration: 30 months, range: 18-48 months), in relationship with non-adherence to denosumab therapy (hazard ratio 4.44; 95% CI: 1.01-19.47) and smaller increase in lumbar spine BMD (hazard ratio 0.85, 95% CI: 0.76-0.94).
CONCLUSIONS: In post-menopausal women at high risk of fractures, the small delay in the administration of denosumab (i.e., not uncommon in clinical practice) was associated with a significant increase in incidence of VFs. Preservation of standard dosing schedule appears to be an important determinant of denosumab effectiveness in the real-life clinical practice.

KEY WORDS: Denosumab; Spinal fractures; Medication adherence; Bone density; Pstmenopausal osteoporosis

inizio pagina